Impact of Flash Glucose Monitoring on the Fear of Hypoglycemia Phenomenon in Adults with Type 1 Diabetes.

Autor: Rodríguez de Vera Gómez P; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Mateo Rodríguez C; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Rodríguez Jiménez B; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Hidalgo Sotelo L; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Peinado Ruiz M; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Torrecillas Del Castillo E; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Ruiz-Aranda D; Department of Psychology, Universidad Loyola Andalucía, Seville, Spain., Serrano Olmedo I; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Candau Martín Á; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain., Martínez-Brocca MA; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Seville, Spain.
Jazyk: angličtina
Zdroj: Diabetes technology & therapeutics [Diabetes Technol Ther] 2024 Jul; Vol. 26 (7), pp. 478-487. Date of Electronic Publication: 2024 Feb 22.
DOI: 10.1089/dia.2023.0370
Abstrakt: Objective: To assess the clinical impact of flash glucose monitoring (FGM) systems on fear of hypoglycemia (FoH) and quality of life in adults with type 1 diabetes mellitus (T1DM). Methods: Prospective quasi-experimental study with a 12-month follow-up. People with T1DM (18-80 years old) and self-monitoring by blood capillary glycemia controls were included. The FH15 questionnaire, a survey validated in Spanish in a comparable study population, was used to diagnose FoH with a cutoff point of 28 points. Results: A total of 181 participants were included, with a FoH prevalence of 69% ( n  = 123). A mean reduction in FH15 score of -4 points (95% confidence interval [-5.5 to -3]; P  < 0.001) was observed, along with an improvement in quality of life (EsDQOL-test (Diabetes Quality of Life, Spanish version), -7 points [-10; -4], P  < 0.001) and satisfaction with treatment (Diabetes Treatment Satisfaction questionnaire, self-reported version [DTSQ-s] test, +4.5 points [4; 5.5], P  < 0.001). At the end of the follow-up, 64.2% of the participants saw an improved FoH intensity, compared to 35.8% who scored the same or higher. This improvement in FoH status was associated with a higher time-in-range at the end of the follow-up ( P  = 0.003), as well as a lower time spent in hyperglycemia ( P  = 0.005). In addition, it was linked to participants with a high baseline FoH levels ( P  < 0.001) and those who were university degree holders ( P  = 0.07). Conclusions: FGM is associated with an overall reduction of FoH in adults with T1DM and with an increase in their quality of life. Nevertheless, a significant percentage of patients may experience an increase of this phenomenon leading to clinical repercussions and a profound impact on quality of life.
Databáze: MEDLINE